RxDoctor Payments Data

Abbigail Woodring

Physician Assistant · Allentown, PANPI 1881328375

Payments from drug & device makers

$664in general payments, 2019–2025

Across 22 payments — averaging $30.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$279
  • Astellas Pharma US Inc$168
  • Medtronic$81
  • Dendreon Pharmaceuticals LLC$36
  • Johnson & Johnson$34
  • Sumitomo Pharma America, Inc.$21
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$59990%
  • Education$6510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664 in reported general payments places this provider in the 70th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,450
Medicare patients
631
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron226$193,570
GemtesaVibegron179$134,678
Trospium Chloride215$15,660
Mirabegron ErMirabegron23$13,924
Tamsulosin Hcl378$8,317
Oxybutynin Chloride ErOxybutynin Chloride206$7,570
Cefpodoxime Proxetil120$6,876
Estradiol73$5,262
Methenamine Hippurate79$5,013
Solifenacin Succinate36$2,433
Tolterodine Tartrate ErTolterodine Tartrate11$1,599
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst52$1,305
Finasteride71$1,217
Desmopressin Acetate13$1,094
Potassium Citrate ErPotassium Citrate13$668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$168$193,570226 claims
Sumitomo Pharma America, Inc.Gemtesa$21$134,678179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →